Richard Daly plans to resign as CEO, CFO, president and director of Neuralstem Inc. after a transitional period.

Daly's resignation from the board did not result from any disagreement on any matter relating to the company's operations, policies or practices, according to Neuralstem.

The company expects to start a search for Daly's replacement to assume his duties after the completion of the transitional period.

Germantown, Md.-based Neuralstem is a clinical-stage biopharmaceutical company that focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds.